ALIGOS THERAPEUTICS INC (ALGS)

US01626L1052 - Common Stock

0.73  +0.02 (+2.79%)

ALIGOS THERAPEUTICS INC

NASDAQ:ALGS (9/28/2023, 7:00:00 PM)

0.73

+0.02 (+2.79%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-03 2023-08-03/amc
Earnings (Next)10-31 2023-10-31/amc
Ins OwnersN/A
Inst Owners65.05%
Market Cap29.50M
Shares40.41M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts82.22
IPO10-16 2020-10-16
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ALGS Daily chart

Company Profile

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The company is headquartered in South San Francisco, California and currently employs 68 full-time employees. The company went IPO on 2020-10-16. The company uses its small molecule and oligonucleotide platforms to develop pharmacologically optimized drug candidates for use in combination regimens. Its primary area of focus is on developing functional cure for nonalcoholic steatohepatitis (NASH) and to develop drug candidates with coronavirus activity, as well as seeks to enhance the rate of functional cure for chronic hepatitis B (CHB). The company has developed a portfolio of differentiated drug candidates for CHB, including a small molecule capsid assembly modulator (CAM-E) and oligonucleotide small interfering ribonucleic acids (siRNA), each of which is designed against clinically validated targets in the hepatitis B virus (HBV) life cycle. Its pipeline includes ALG-055009 for the treatment of NASH; ALG-000184 and ALG-125755 for CHB, and ALG-097558 for coronavirus.

Company Info

ALIGOS THERAPEUTICS INC

One Corporate Dr., 2Nd Floor, 2nd Floor

South San Francisco CALIFORNIA 94080

P: 18004666059.0

CEO: Lawrence M. Blatt

Employees: 68

Website: https://www.aligos.com/

ALGS News

News Image8 days ago - Aligos TherapeuticsAligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009

- Phase 2a NASH protocol on track to be submitted to the IND in Q4 2023, enrollment expected to begin in Q1 2024

News Image8 days ago - Aligos TherapeuticsAligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009

- Phase 2a NASH protocol on track to be submitted to the IND in Q4 2023, enrollment expected to begin in Q1 2024...

News Image2 months ago - Aligos TherapeuticsAligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results
News Image2 months ago - Aligos TherapeuticsAligos Therapeutics to Announce Second Quarter Results on August 03, 2023
News Image2 months ago - Aligos TherapeuticsAligos Therapeutics to Announce Second Quarter Results on August 03, 2023

SOUTH SAN FRANCISCO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage...

News Image2 months ago - Aligos TherapeuticsAligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009

ALGS Twits

Here you can normally see the latest stock twits on ALGS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example